Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Level Biotechnology stock price, quote, forecast and news

3118.TWO
TW0003118006

Price

34.45
Today +/-
+0
Today %
+0 %
P

Level Biotechnology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Level Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Level Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Level Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Level Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Level Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Level Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Level Biotechnology’s growth potential.

Level Biotechnology Revenue, EBIT and net profit per share

DateLevel Biotechnology RevenueLevel Biotechnology EBITLevel Biotechnology Net Income
2023660.61 M undefined67.55 M undefined62.91 M undefined
2022593.01 M undefined64.9 M undefined58.47 M undefined
2021677.28 M undefined78.96 M undefined68.18 M undefined
2020672.49 M undefined65.91 M undefined58.04 M undefined
2019638.9 M undefined56.45 M undefined47.4 M undefined
2018629.03 M undefined49.16 M undefined38.91 M undefined
2017577.63 M undefined80.79 M undefined68.31 M undefined
2016513.54 M undefined74.53 M undefined63.26 M undefined
2015519.97 M undefined85.48 M undefined78.39 M undefined
2014533.31 M undefined88.67 M undefined76.84 M undefined
2013528.97 M undefined74.76 M undefined64.61 M undefined
2012470.03 M undefined58.21 M undefined52.87 M undefined
2011497.09 M undefined71.4 M undefined60.3 M undefined
2010527.45 M undefined76.56 M undefined72.05 M undefined
2009468.52 M undefined50.26 M undefined48.16 M undefined
2008462.58 M undefined66.42 M undefined60.31 M undefined
2007390.62 M undefined47.25 M undefined40.11 M undefined
2006379.55 M undefined53.76 M undefined39.03 M undefined
2005301.47 M undefined27.9 M undefined29.1 M undefined
2004255.03 M undefined16.99 M undefined22.69 M undefined

Level Biotechnology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
217255301379390462468527497470528533519513577629638672677593660
-17.5118.0425.912.9018.461.3012.61-5.69-5.4312.340.95-2.63-1.1612.489.011.435.330.74-12.4111.30
31.3435.2940.2037.7337.6939.1836.5437.0037.6336.3835.9838.6539.1137.6235.8829.4130.5631.4034.2734.0633.18
6890121143147181171195187171190206203193207185195211232202219
21627534766507671587488857480495665786467
0.926.278.9713.9812.0514.2910.6814.4214.2912.3414.0216.5116.3814.4213.867.798.789.6711.5210.7910.15
02229394060487260526476786368384758685862
--31.8234.482.5650.00-20.0050.00-16.67-13.3323.0818.752.63-19.237.94-44.1223.6823.4017.24-14.716.90
---------------------
---------------------
25.6323.628.6428.6328.6331.332.632.5532.632.5632.5832.6132.6432.6332.6232.5832.5932.632.6732.6732.66
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The Level Biotechnology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Level Biotechnology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Level Biotechnology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Level Biotechnology's financial health and stability.

Assets

Level Biotechnology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Level Biotechnology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Level Biotechnology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Level Biotechnology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
022293940604872606377919576834959728473
912182120202120181614131513151620201919
-4-2-536910000000000000
5-3224-2423-3-1940-21-246-1-6-8-27-3931-852-24
10316-2000-1-2-2-2-6-300-1-1-1-2
00232000000000000000
0034441351513914161711158131517
2136946878651134565395101977971261098315565
-17-116-103-7-8-7-7-4-2-2-2-3-5-7-10-2-2-2-9-6
-21-122-103-1410-22-5-80-1-1-5-7-11-26-13-2-2-8-10
-3-60-618-141-4100-1-2-4-16-10000-3
00000000000000000000
-26828-27-25-570000000000-2-2-2-2
03400010600000000000000
-210316-43-4315-55-46-46-65-55-54-64-71-61-61-34-44-54-64
---2.00-2.00-3.00-2.00--------------
00-10-13-14-30-55-46-46-64-55-55-64-71-61-61-32-42-51-61
-1-16-18-115480-10789-14394125-4-17-47713592-9
3.76-112.78-34.2138.279.0178.9243.95129.595450.8393.697.7692.5571.5660.4624.26106.680.69146.858.33
00000000000000000000

Level Biotechnology stock margins

The Level Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Level Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Level Biotechnology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Level Biotechnology's sales revenue. A higher gross margin percentage indicates that the Level Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Level Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Level Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Level Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Level Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Level Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Level Biotechnology Margin History

Level Biotechnology Gross marginLevel Biotechnology Profit marginLevel Biotechnology EBIT marginLevel Biotechnology Profit margin
202333.23 %10.23 %9.52 %
202234.16 %10.94 %9.86 %
202134.33 %11.66 %10.07 %
202031.48 %9.8 %8.63 %
201930.65 %8.83 %7.42 %
201829.49 %7.82 %6.19 %
201736 %13.99 %11.83 %
201637.74 %14.51 %12.32 %
201539.11 %16.44 %15.08 %
201438.68 %16.63 %14.41 %
201336.08 %14.13 %12.21 %
201236.46 %12.38 %11.25 %
201137.75 %14.36 %12.13 %
201037.16 %14.52 %13.66 %
200936.51 %10.73 %10.28 %
200839.22 %14.36 %13.04 %
200737.88 %12.1 %10.27 %
200637.81 %14.17 %10.28 %
200540.23 %9.25 %9.65 %
200435.38 %6.66 %8.9 %

Level Biotechnology Stock Sales Revenue, EBIT, Earnings per Share

The Level Biotechnology earnings per share therefore indicates how much revenue Level Biotechnology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Level Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Level Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Level Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Level Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Level Biotechnology Revenue, EBIT and net profit per share

DateLevel Biotechnology Sales per ShareLevel Biotechnology EBIT per shareLevel Biotechnology Earnings per Share
202320.23 undefined2.07 undefined1.93 undefined
202218.15 undefined1.99 undefined1.79 undefined
202120.73 undefined2.42 undefined2.09 undefined
202020.63 undefined2.02 undefined1.78 undefined
201919.6 undefined1.73 undefined1.45 undefined
201819.31 undefined1.51 undefined1.19 undefined
201717.71 undefined2.48 undefined2.09 undefined
201615.74 undefined2.28 undefined1.94 undefined
201515.93 undefined2.62 undefined2.4 undefined
201416.35 undefined2.72 undefined2.36 undefined
201316.24 undefined2.29 undefined1.98 undefined
201214.44 undefined1.79 undefined1.62 undefined
201115.25 undefined2.19 undefined1.85 undefined
201016.21 undefined2.35 undefined2.21 undefined
200914.37 undefined1.54 undefined1.48 undefined
200814.78 undefined2.12 undefined1.93 undefined
200713.64 undefined1.65 undefined1.4 undefined
200613.26 undefined1.88 undefined1.36 undefined
200510.53 undefined0.97 undefined1.02 undefined
200410.81 undefined0.72 undefined0.96 undefined

Level Biotechnology business model

Level Biotechnology is one of the most popular companies on Eulerpool.com.

Level Biotechnology historical P/E ratio, EBIT, and P/S ratio.

Level Biotechnology shares outstanding

The number of shares was Level Biotechnology in 2023 — This indicates how many shares 32.657 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Level Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Level Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Level Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Level Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Level Biotechnology dividend history and estimates

In 2023, Level Biotechnology paid a dividend amounting to 1.7 TWD. Dividend means that Level Biotechnology distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Level Biotechnology provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Level Biotechnology’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Level Biotechnology's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Level Biotechnology Dividend History

DateLevel Biotechnology Dividend
20231.7 undefined
20221.9 undefined

Level Biotechnology dividend payout ratio

In 2023, Level Biotechnology had a payout ratio of 106.15%. The payout ratio indicates the percentage of the company's profits that Level Biotechnology distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Level Biotechnology represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Level Biotechnology could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Level Biotechnology's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Level Biotechnology Payout Ratio History

DateLevel Biotechnology Payout ratio
2023106.15 %
2022106.15 %
2021106.15 %
2020106.15 %
2019106.15 %
2018106.15 %
2017106.15 %
2016106.15 %
2015106.15 %
2014106.15 %
2013106.15 %
2012106.15 %
2011106.15 %
2010106.15 %
2009106.15 %
2008106.15 %
2007106.15 %
2006106.15 %
2005106.15 %
2004106.15 %
Unfortunately, there are currently no price targets and forecasts available for Level Biotechnology.

Level Biotechnology list of shareholders

%
Name
Stocks
Change
Date
8.65 % Chiu (Chun Lung)2,806,00004/30/2023
4.00 % Chang (Yung Feng)1,299,00004/30/2023
3.33 % Emerson Investment Ltd.1,082,00004/30/2023
3.08 % Hui Ling Investment Ltd.998,00004/30/2023
2.48 % Chiu (Yih Chun)805,00004/30/2023
2.31 % Han Chuan Investment Limited750,00004/30/2023
2.25 % Lin (Chin Yuan-d)730,00004/30/2023
2.10 % Chen (Kuo Tung)680,00004/30/2023
2.03 % Wang (Sheng Hui-a)660,00004/30/2023
1.56 % Shao (Li Feng)505,000-5,0004/30/2023
1
2

Most common questions regarding Level Biotechnology

What is the P/E ratio of Level Biotechnology 2024?

The P/E ratio cannot be calculated for Level Biotechnology at the moment.

What is the P/S ratio of Level Biotechnology 2024?

The P/S cannot be calculated for Level Biotechnology currently.

What is the AlleAktien quality score of Level Biotechnology?

The AlleAktien quality score for Level Biotechnology is 3/10.

What is the revenue of Level Biotechnology 2024?

The revenue cannot currently be calculated for Level Biotechnology.

How high is the profit of Level Biotechnology 2024?

The profit cannot currently be calculated for Level Biotechnology.

What is the business model of Level Biotechnology

No history available for Level Biotechnology.

What is the Level Biotechnology dividend?

Level Biotechnology pays a dividend of 1.9 TWD distributed over payouts per year.

How often does Level Biotechnology pay dividends?

The dividend cannot currently be calculated for Level Biotechnology or the company does not pay out a dividend.

What is the Level Biotechnology ISIN?

The ISIN of Level Biotechnology is TW0003118006.

What is the Level Biotechnology ticker?

The ticker of Level Biotechnology is 3118.TWO.

How much dividend does Level Biotechnology pay?

Over the past 12 months, Level Biotechnology paid a dividend of 1.7 TWD . This corresponds to a dividend yield of about 4.93 %. For the coming 12 months, Level Biotechnology is expected to pay a dividend of 1.7 TWD.

What is the dividend yield of Level Biotechnology?

The current dividend yield of Level Biotechnology is 4.93 %.

When does Level Biotechnology pay dividends?

Level Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Level Biotechnology?

Level Biotechnology paid dividends every year for the past 2 years.

What is the dividend of Level Biotechnology?

For the upcoming 12 months, dividends amounting to 1.7 TWD are expected. This corresponds to a dividend yield of 4.93 %.

In which sector is Level Biotechnology located?

Level Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Level Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Level Biotechnology from 7/12/2024 amounting to 1.7 TWD, you needed to have the stock in your portfolio before the ex-date on 6/18/2024.

When did Level Biotechnology pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Level Biotechnology in the year 2023?

In the year 2023, Level Biotechnology distributed 1.9 TWD as dividends.

In which currency does Level Biotechnology pay out the dividend?

The dividends of Level Biotechnology are distributed in TWD.

All fundamentals about Level Biotechnology

Our stock analysis for Level Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Level Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.